KalVista Pharmaceuticals, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| VR ADVISER, LLC | 11/14/2024 | 6.25 M | $72.37 M | 0.00% | 13.52% |
| TANG CAPITAL MANAGEMENT LLC | 11/14/2024 | 4.32 M | $50.04 M | 2.43% | 9.35% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 11/14/2024 | 4.21 M | $48.78 M | 0.48% | 9.11% |
| VESTAL POINT CAPITAL, LP | 11/14/2024 | 4.00 M | $46.32 M | 73.91% | 8.65% |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 11/15/2024 | 3.69 M | $42.71 M | 0.00% | 7.98% |
| CAPITAL WORLD INVESTORS | 11/13/2024 | 3.37 M | $39.07 M | 4.54% | 7.30% |
| BLACKROCK FUNDING, INC. /DE | 11/13/2024 | 3.06 M | $35.46 M | 100.00% | 6.62% |
| VANGUARD GROUP INC | 11/13/2024 | 2.15 M | $24.90 M | 8.03% | 4.65% |
| BOXER CAPITAL, LLC | 11/14/2024 | 1.59 M | $18.41 M | 0.00% | 3.44% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 11/14/2024 | 1.42 M | $16.44 M | -30.74% | 3.07% |
| GREAT POINT PARTNERS LLC | 11/13/2024 | 1.30 M | $15.05 B | -2.92% | 2.81% |
| STATE STREET CORP | 11/14/2024 | 1.27 M | $14.73 M | 68.11% | 2.75% |
| BIOIMPACT CAPITAL LLC | 11/13/2024 | 896,915 | $10.39 M | 1.70% | 1.94% |
| EMERALD ADVISERS, LLC | 10/29/2024 | 835,988 | $9.68 M | 29.83% | 1.81% |
| GEODE CAPITAL MANAGEMENT, LLC | 11/12/2024 | 830,984 | $9.62 M | 3.07% | 1.80% |
| DAFNA CAPITAL MANAGEMENT LLC | 11/14/2024 | 723,678 | $8.38 M | -10.32% | 1.57% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 10/29/2024 | 650,980 | $7.54 M | 22.97% | 1.41% |
| WOODLINE PARTNERS LP | 11/14/2024 | 608,253 | $7.04 M | 304.26% | 1.32% |
| DIMENSIONAL FUND ADVISORS LP | 11/07/2024 | 607,036 | $7.03 M | 13.47% | 1.31% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 11/14/2024 | 574,558 | $6.65 M | 2.44% | 1.24% |
| SATURN V CAPITAL MANAGEMENT LLC | 11/14/2024 | 556,489 | $6.44 M | -50.69% | 1.20% |
| JANE STREET GROUP, LLC | 11/15/2024 | 499,200 | $5.78 M | 100.00% | 1.08% |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 11/13/2024 | 431,232 | $5.32 M | -7.86% | 0.93% |
| JEFFERIES FINANCIAL GROUP INC. | 11/14/2024 | 375,000 | $4.34 M | 114.29% | 0.81% |
| FIRST TURN MANAGEMENT, LLC | 11/07/2024 | 355,000 | $4.11 M | -66.49% | 0.77% |
| ROSALIND ADVISORS, INC. | 10/30/2024 | 303,864 | $3.52 M | -10.10% | 0.66% |
| MORGAN STANLEY | 11/14/2024 | 297,402 | $3.44 M | -12.16% | 0.64% |
| READYSTATE ASSET MANAGEMENT LP | 11/14/2024 | 180,000 | $2.08 M | 100.00% | 0.39% |
| QUBE RESEARCH & TECHNOLOGIES LTD | 11/14/2024 | 178,608 | $2.07 M | 503.63% | 0.39% |
| NAN FUNG GROUP HOLDINGS LTD | 11/13/2024 | 154,522 | $1.79 M | -29.53% | 0.33% |
| UBS OCONNOR LLC | 11/14/2024 | 135,552 | $1.57 M | 10.24% | 0.29% |
| GOLDMAN SACHS GROUP INC | 11/14/2024 | 134,041 | $1.55 M | -37.04% | 0.29% |
| CITADEL ADVISORS LLC | 11/14/2024 | 127,249 | $1.47 M | 576.07% | 0.28% |
| WELLINGTON MANAGEMENT GROUP LLP | 11/14/2024 | 117,923 | $1.37 M | 40.35% | 0.26% |
| RUSSELL INVESTMENTS GROUP, LTD. | 11/13/2024 | 115,992 | $1.34 M | 47.42% | 0.25% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11/12/2024 | 110,720 | $1.28 M | 0.11% | 0.24% |
| BANK OF NEW YORK MELLON CORP | 11/12/2024 | 105,611 | $1.22 M | -22.12% | 0.23% |
| CITADEL ADVISORS LLC | 11/14/2024 | 98,000 | $1.13 M | 910.31% | 0.21% |
| ZIMMER PARTNERS, LP | 11/14/2024 | 95,704 | $1.11 M | 52.63% | 0.21% |
| D. E. SHAW & CO., INC. | 11/14/2024 | 89,929 | $1.04 M | -10.13% | 0.19% |
| BIRCHVIEW CAPITAL, LP | 11/14/2024 | 82,000 | $949,560 | 78.26% | 0.18% |
| NUVEEN ASSET MANAGEMENT, LLC | 11/14/2024 | 80,443 | $931,530 | 0.00% | 0.17% |
| BARCLAYS PLC | 11/19/2024 | 67,222 | $778,000 | 418.49% | 0.15% |
| FMR LLC | 11/13/2024 | 66,423 | $769,178 | 22.95% | 0.14% |
| CLARIVEST ASSET MANAGEMENT LLC | 11/12/2024 | 57,096 | $672,591 | 0.00% | 0.12% |
| STATE OF WISCONSIN INVESTMENT BOARD | 11/14/2024 | 54,468 | $630,739 | -10.35% | 0.12% |
| BANK OF AMERICA CORP /DE/ | 11/14/2024 | 52,694 | $610,196 | -15.70% | 0.11% |
| RHUMBLINE ADVISERS | 11/12/2024 | 50,279 | $582,221 | -5.54% | 0.11% |
| RAFFERTY ASSET MANAGEMENT, LLC | 11/13/2024 | 43,830 | $507,551 | 100.00% | 0.09% |
| UBS GROUP AG | 11/14/2024 | 43,429 | $502,908 | 223.95% | 0.09% |
KalVista Pharmaceuticals, Inc.institutional Ownership - FAQ's
During the previous two years, 148 institutional investors and hedge funds held shares of KalVista Pharmaceuticals, Inc.. The most heavily invested institutionals were:
VR Adviser, LLC: 6.25 M
TANG CAPITAL MANAGEMENT LLC: 4.32 M
SUVRETTA CAPITAL MANAGEMENT, LLC: 4.21 M
Vestal Point Capital, LP: 4 M
Frazier Life Sciences Management, L.P.: 3.69 M
Capital World Investors: 3.37 M
104.71% of KalVista Pharmaceuticals, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 51.84 M shares in the last 24 months. This purchase volume represents approximately $457.79 M in transactions.